EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

European Urology

Volumn 59, Issue 6, 2011, Pages 997-1008

  Babjuk, Marko ^a   Oosterlinck, Willem ^b   Sylvester, Richard ^c   Kaasinen, Eero ^d   Böhle, Andreas ^e   Palou Redorta, Juan ^f   Rouprêt, Morgan ^g  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c EORTC DATA CENTER   (Belgium)

^d HYVINKÄÄ HOSPITAL   (Finland)

^e HELIOS AGNES KARLL HOSPITAL   (Germany)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Bacillus Calmette Gu rin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BCG VACCINATION; BLADDER BIOPSY; BLADDER CANCER; BLADDER CARCINOMA; BLADDER CARCINOMA IN SITU; BLADDER PAPILLOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CARCINOMA IN SITU; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTITIS; CYSTOSCOPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EUROPE; EVIDENCE BASED PRACTICE; FLUORESCENCE CYSTOSCOPY; FOLLOW UP; HEALTH CARE ORGANIZATION; HEMATURIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTRAVENOUS UROGRAPHY; META ANALYSIS; NONMUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PHOTODYNAMIC DIAGNOSIS; PHOTODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; SCORING SYSTEM; SEPSIS; SYMPTOM; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; URINALYSIS; URINE CYTOLOGY; UROGENITAL ENDOSCOPY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79955593955     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.017     Document Type: Article

References (72)

1. W. Oosterlinck, B. Lobel, G. Jakse, P.-U. Malmström, M. Stöckle, C. Sternberg The EAU Working Group on Oncological Urology Guidelines on bladder cancer Eur Urol 41 2002 105 112 (Pubitemid 35428874)
2. Oxford Centre for Evidence-based Medicine - levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http://www.cebm.net/index. aspx?o=1025.
3. Ferlay J, Bray F, Pisani P, Parkin DM. Globcan 2002, cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, v.2.0. Lyon, France: IARCC Press, 2004.
4. J. Ferlay, G. Randi, and C. Bosetti Declining mortality from bladder cancer in Europe BJU Int 101 2008 11 19 (Pubitemid 350233570)
5. M.P.A. Zeegers, G.M.H. Swaen, and I. Kant Occupational risk factors for male bladder cancer: results from a population-based case cohort study in the Netherlands Occup Environ Med 58 2001 590 596
6. M.P. Zeegers, F.E. Tan, E. Dorant, and P.A. van den Brandt The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies Cancer 89 2000 630 639 (Pubitemid 30640110)
7. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM classification of malignant tumors (UICC International Union Against Cancer) ed 7. 2009 Wiley-Blackwell New York, NY 262 265
8. G. Sauter, F. Algaba, and M. Amin Tumours of the urinary system: non-invasive urothelial neoplasias J.N. Eble, G. Sauter, Epstein Jl I. Sesterhenn, WHO classification of tumours of the urinary system and male genital organs 2004 IARCC Press Lyon, France
9. M. Burger, M.N.M. van der Aa, and J.M.M. van Oers Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study Eur Urol 54 2008 835 844
10. C.C. Pan, Y.H. Chang, and K.K. Chen Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases Am J Clin Pathol 133 2010 788 795
11. M. May, S. Brookman-Amissah, and J. Roigas Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications Eur Urol 57 2010 850 858
12. A. Van der Meijden, R. Sylvester, and L. Collette The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials J Urol 164 2000 1533 1537
13. R. Sylvester, A. van der Meijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 Suppl 1 2005 90 107 (Pubitemid 43049611)
14. J. Palou, F. Rodriguez-Rubio, and J. Huguet Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumors J Urol 174 2005 859 861 (Pubitemid 41140611)
15. F. Millan-Rodriguez, G. Chechile-Toniolo, and J. Salvador-Bayarri Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups J Urol 164 2000 1183 1187
16. V.B. Lokeshwar, T. Habuchi, and H.B. Grossman Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers Urology 66 Suppl 6A 2005 35 63 (Pubitemid 43049608)
17. M.-P. Raitanen, R. Aine, and E. Rintala Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis Eur Urol 41 2002 284 289 (Pubitemid 35303426)
18. B.W.G. van Rhijn, H.G. van der Poel, and T.H. van der Kwast Cytology and urinary markers for the diagnosis of bladder cancer Eur Urol Suppl 8 2009 536 541
19. H.B. Grossman, E. Messing, and M. Soloway Detection of bladder cancer using a point-of-care proteomic assay JAMA 293 2005 810 816 (Pubitemid 40250364)
20. T. Hajdinjak UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing Urol Oncol 26 2008 645 651
21. G. Mowatt, S. Zhu, and M. Kilonzo Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer Health Technol Assess 14 2010 1 331
22. Y. Lotan, R.S. Svatek, and N. Malats Screening for bladder cancer: a perspective World J Urol 26 2008 13 18
23. B.W.G. Van Rhijn, H.G. van der Poel, and T.H. van der Kwast Urine markers for bladder cancer surveillance: a systematic review Eur Urol 47 2005 736 748 (Pubitemid 40745338)
24. A. Lopez-Beltran, P. Bassi, M. Pavone-Macaluso, and R. Montironi Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis Eur Urol 45 2004 257 266 (Pubitemid 38221396)
25. M. Brausi, L. Collette, K. Kurth EORTC Genito-Urinary Tract Cancer Collaborative Group Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
26. A. van der Meijden, W. Oosterlinck, M. Brausi, K.-H. Kurth, R. Sylvester, C. deBalincourt Members of the EORTC-GU Group Superficial Bladder Committee Significance of bladder biopsies in Ta,T1 bladder tumors: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur Urol 35 1999 267 271 (Pubitemid 29154829)
27. M.U. Mungan, A.E. Canda, E. Tuzel, K. Yorukoglu, and Z. Kirkali Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder Eur Urol 48 2005 760 763 (Pubitemid 41495374)
28. I. Kausch, M. Sommerauer, and F. Montorsi Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
29. M.C. Schumacher, S. Holmäng, and T. Davidsson Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study Eur Urol 57 2010 293 299
30. A. Stenzl, M. Burger, and Y. Fradet Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer J Urol 184 2010 1907 1913
31. G. Jakse, F. Algaba, P.-U. Malmström, and W. Oosterlinck A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45 2004 539 546 (Pubitemid 38481678)
32. R.T. Divrik, Ü. Yildirim, F. Zorlu, and H. Özen The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial J Urol 175 2006 1641 1644
33. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
34. J. Fernandez-Gomez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model J Urol 182 2009 2195 2203
35. D.L. Lamm Carcinoma in situ Urol Clin North Am 19 1992 499 508
36. D.C. Chade, S.F. Shariat, and G. Godoy Clinical outcomes of primary bladder carcinoma in situ in a contemporary series J Urol 184 2010 74 80
37. R. Sylvester, W. Oosterlinck, and A. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190 (Pubitemid 38625431)
38. I. Berrum-Svennung, T. Granfors, and S. Jahnson A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101 105
39. S. Gudjónsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
40. E. Kaasinen, E. Rintala, and P. Hellström Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167 174
41. K. Hendricksen, W.P.J. Witjes, and J.G. Idema Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer Eur Urol 53 2008 984 991
42. J.R. Oddens, A.P.M. van der Meijden, and R. Sylvester One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol 46 2004 336 338 (Pubitemid 39078567)
43. A. Pawinski, R. Sylvester, and K.H. Kurth A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer J Urol 156 1996 1934 1941 (Pubitemid 26378022)
44. M. Huncharek, J.-F. Geschwind, B. Witherspoon, R. McGarry, and D. Adcock Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials J Clin Epidemiol 53 2000 676 680 (Pubitemid 30609619)
45. M. Huncharek, R. McGarry, and B. Kupelnick Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis Anticancer Res 21 2001 765 770
46. R.J. Sylvester, W. Oosterlinck, and J.A. Witjes The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials Eur Urol 53 2008 709 719
47. J.L. Au, R.A. Badalament, M.G. Wientjes International Mitomycin C Consortium Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597 604 (Pubitemid 32409627)
48. M. Kuroda, T. Niijima, T. Kotake, H. Akaza, and S. Hinotsu Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer - the 6th trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml Eur Urol 45 2004 600 605 (Pubitemid 38481687)
49. M.D. Shelley, H. Kynaston, and J. Court A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer BJU Int 88 2001 209 216 (Pubitemid 32863039)
50. R.F. Han, and J.G. Pan Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials Urology 67 2006 1216 1223 (Pubitemid 43818066)
51. M.D. Shelley, T.J. Wilt, J. Court, B. Coles, H. Kynaston, and M.D. Mason Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 2004 485 490
52. A. Böhle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95 (Pubitemid 35461559)
53. M. Duchek, R. Johansson, and S. Jahnson Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-α2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study Eur Urol 57 2010 25 31
54. R. Järvinen, E. Kaasinen, and A. Sankila Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up Eur Urol 56 2009 260 265
55. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
56. P.-U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
57. R.J. Sylvester, van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
58. A. Böhle, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682 687
59. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129 (Pubitemid 30169376)
60. J.A. Martinez-Pineiro, L. Martinez-Pineiro, and E. Solsona Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242 1247 (Pubitemid 41318691)
61. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398 1406 (Pubitemid 47449726)
62. A.P.M. van der Meijden, R.J. Sylvester, W. Oosterlinck, W. Hoeltl, A.V. Bono for the EORTC Genito-Urinary Tract Cancer Group Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increase toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial Eur Urol 44 2003 429 434 (Pubitemid 37185667)
63. J.A. Witjes, J. Palou, and M. Soloway Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events Eur Urol Suppl 7 2008 667 674
64. R.J. Sylvester, A.P.M. van der Meijden, and J.A. Witjes Bacillus Calmette-Guérin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86 92
65. J. Palou, J. Baniel, and L. Klotz Urothelial carcinoma of the prostate Urology 69 Suppl 2007 50 61 (Pubitemid 46186480)
66. H. Herr, and G. Dalbagni Defining bacillus Calmette-Guérin refractory superficial bladder tumors J Urol 169 2003 1706 1708 (Pubitemid 36443476)
67. E. Solsona, I. Iborra, R. Dumont, J. Rubio-Briones, J. Casanova, and S. Almenar The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685 689 (Pubitemid 30637602)
68. S.P. Lerner, C.M. Tangen, and H. Sucharew Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non muscle invasive bladder cancer Urol Oncol 27 2009 155 159
69. G.V. Raj, H. Herr, and A.M. Serio Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer J Urol 177 2007 1283 1286 (Pubitemid 46435978)
70. O.N. Gofrit, D. Pode, A. Lazar, R. Katz, and A. Shapiro Watchful waiting policy in recurrent Ta G1 bladder tumors Eur Urol 49 2006 303 307
71. H.W. Herr, S.M. Donat, and V.E. Reuter Management of low grade papillary bladder tumors J Urol 178 2007 2201 2205
72. S. Holmang, and S.L. Johansson Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression J Urol 176 2002 1634 1637 (Pubitemid 34240688)